Skip to Content

Adlarity FDA Approval Status

FDA Approved: No
Brand name: Adlarity
Generic name: donepezil
Dosage form: Transdermal System
Company: Corium, Inc.
Treatment for: Alzheimer's Disease

Adlarity (donepezil transdermal system) is an investigational, once-weekly transdermal formulation of Aricept (donepezil HCl) in development for the treatment of Alzheimer’s disease.

Development Timeline for Adlarity

Jan 27, 2020Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for Adlarity (donepezil transdermal system) for the Treatment of Alzheimer’s Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.